Xia C, Dong X, Li H, Cao M, Sun D, He S et al (2022) Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J 135(05):584–590
Article
PubMed
PubMed Central
Google Scholar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
Article
PubMed
Google Scholar
Kew MC (2015) Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. Ann Hepatol 12(2):173–182
Article
Google Scholar
Control, C.f.D. and Prevention (2001) Health information for international travel 2001–2002. International Medical Pub
Cui Y, Jia J (2013) Update on epidemiology of hepatitis B and C in C hina. J Gastroenterol Hepatol 28:7–10
Article
PubMed
Google Scholar
Levrero M, Zucman-Rossi J (2016) Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 64(1):S84–S101
Article
CAS
PubMed
Google Scholar
Sohn W, Cho J-Y, Kim JH, Lee JI, Kim HJ, Woo M-A et al (2017) Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B. Clin Mol Hepatol 23(2):170
Article
PubMed
PubMed Central
Google Scholar
Tang LS, Covert E, Wilson E, Kottilil S (2018) Chronic hepatitis B infection: a review. JAMA 319(17):1802–1813
Article
CAS
PubMed
Google Scholar
Schoggins JW, Rice CM (2011) Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 1(6):519–525
Article
CAS
PubMed
PubMed Central
Google Scholar
Clark DN, Hu J (2015) Hepatitis B virus reverse transcriptase-target of current antiviral therapy and future drug development. Antiviral Res 123:132–137
Article
CAS
PubMed
PubMed Central
Google Scholar
Terrault NA, Bzowej NH, Chang K-M, Hwang JP, Jonas MM, Murad MH (2016) AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63(1):261
Article
PubMed
Google Scholar
Niro G, Ippolito A, Fontana R, Valvano M, Gioffreda D, Iacobellis A et al (2013) Long-term outcome of hepatitis B virus-related C hronic H epatitis under protracted nucleos(t)ide analogues. J Viral Hepat 20(7):502–509
Article
CAS
PubMed
Google Scholar
Wong GH, Tse YK, Yip TF, Chan HY, Tsoi KF, Wong VS (2017) Long-term use of oral nucleos (t) ide analogues for chronic hepatitis B does not increase cancer risk—a cohort study of 44 494 subjects. Aliment Pharmacol Therap 45(9):1213–1224
Article
CAS
Google Scholar
Yin J, Li N, Han Y, Xue J, Deng Y, Shi J et al (2013) Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 31(29):3647–3655
Article
CAS
PubMed
Google Scholar
Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC et al (2013) Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 11(1):88–94
Article
PubMed
CAS
Google Scholar
Tsai M-C, Chen C-H, Hung C-H, Lee C-M, Chiu K-W, Wang J-H et al (2014) A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study. Clin Microbiol Infect 20(2):O90–O100
Article
CAS
PubMed
Google Scholar
Coffin C, Rezaeeaval M, Pang J, Alcantara L, Klein P, Burak K et al (2014) The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos (t) ide analogue therapy. Aliment Pharmacol Therap 40(11–12):1262–1269
Article
CAS
Google Scholar
Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M et al (2015) Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. J Viral Hepat 22(5):504–510
Article
CAS
PubMed
Google Scholar
Su F, Berry K, Ioannou GN (2021) No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut 70(2):370–378
CAS
PubMed
Google Scholar
Shin JW, Jeong J, Jung SW, Lee SB, Park BR, Kim M-J et al (2021) Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir or tenofovir. Dig Dis Sci 66(5):1739–1750
Article
CAS
PubMed
Google Scholar
Na JE, Sinn DH, Lee JH, Jang HJ, Baek SY, Kim KA et al (2021) Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. J Viral Hepat 28(10):1392–1399
Article
CAS
PubMed
Google Scholar
Wang X-H, Hu Z-L, Fu Y-Z, Hou J-Y, Li W-X, Zhang Y-J et al (2022) Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. J Gastroenterol 57(3):185–198
Article
CAS
PubMed
Google Scholar
Jeong S, Shin HP, Kim HI (2022) Real-world single-center comparison of the safety and efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in patients with chronic hepatitis B. Intervirology 65(2):94–103
Article
CAS
PubMed
Google Scholar
Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M et al (2020) Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol 73(5):1037–1045
Article
CAS
PubMed
Google Scholar
Riveiro-Barciela M, Tabernero D, Calleja JL, Lens S, Manzano ML, Rodríguez FG et al (2017) Effectiveness and safety of entecavir or tenofovir in a Spanish cohort of chronic hepatitis B patients: validation of the page-B score to predict hepatocellular carcinoma. Dig Dis Sci 62(3):784–793
Article
CAS
PubMed
Google Scholar
Kim BG, Park NH, Lee SB, Lee H, Lee BU, Park JH et al (2018) Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir. J Viral Hepat 25(12):1565–1575
Article
CAS
PubMed
Google Scholar
Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim Y-S (2019) Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol 5(1):30–36
Article
PubMed
Google Scholar
Oh H, Yoon EL, Jun DW, Ahn SB, Lee H-Y, Jeong JY et al (2020) No difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with entecavir vs tenofovir. Clin Gastroenterol Hepatol 18(12):2793–2802
Article
CAS
PubMed
Google Scholar
Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS et al (2020) Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut 69(7):1301–1308
Article
CAS
PubMed
Google Scholar
Chen C-H, Chen C-Y, Wang J-H, Lai H-C, Hung C-H, Lu S-N et al (2020) Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan-a retrospective study. Am J Cancer Res 10(11):3882
CAS
PubMed
PubMed Central
Google Scholar
Ha I, Chung JW, Jang ES, Jeong S-H, Kim J-W (2020) Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: a propensity score matching analysis. J Gastroenterol Hepatol 35(10):1774–1781
Article
PubMed
Google Scholar
Chang T-S, Yang Y-H, Chen W-M, Shen C-H, Tung S-Y, Yen C-W et al (2021) Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep 11(1):1–14
CAS
Google Scholar
Lee JH, Kim BK, Park SY, Tak WY, Park JY, Ahn SH et al (2021) The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus–related hepatocellular carcinoma. Eur J Intern Med 89:48–55
Article
CAS
PubMed
Google Scholar
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283(15):2008–2012
Article
CAS
PubMed
Google Scholar
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560
Article
PubMed
PubMed Central
Google Scholar
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1–e34
Article
PubMed
Google Scholar
Gupta A, Das A, Majumder K, Arora N, Mayo HG, Singh PP et al (2018) Obesity is independently associated with increased risk of hepatocellular cancer-related mortality. Am J Clin Oncol 41(9):874–881
Article
PubMed
PubMed Central
Google Scholar
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
Article
PubMed
PubMed Central
Google Scholar
Sheikhbahaei S, Trahan TJ, Xiao J, Taghipour M, Mena E, Connolly RM et al (2016) FDG-PET/CT and MRI for evaluation of pathologic response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis of diagnostic accuracy studies. Oncologist 21(8):931–939
Article
PubMed
PubMed Central
CAS
Google Scholar
Nassal M (2015) HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64(12):1972–1984
Article
CAS
PubMed
Google Scholar
Wong DK-H, Seto W-K, Fung J, Ip P, Huang F-Y, Lai C-L et al (2013) Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol 11(8):1004–1010
Article
CAS
PubMed
Google Scholar
Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM et al (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67(4):1560–1599
Article
PubMed
Google Scholar
Liver, E.A.F.T.S.O.T. (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57(1):167–185
Article
Google Scholar
Buti M, Brosa M, Casado MA, Rueda M, Esteban R (2009) Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 51(4):640–646
Article
CAS
PubMed
Google Scholar
Jayakumar R, Joshi YK, Singh S (2012) Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. J Lab Phys 4(01):010–016
CAS
Google Scholar
Honda M, Shirasaki T, Terashima T, Kawaguchi K, Nakamura M, Oishi N et al (2016) Hepatitis B virus (HBV) core-related antigen during nucleos (t) ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma. J Infect Dis 213(7):1096–1106
Article
CAS
PubMed
Google Scholar
Wong GH, Tse YK, Chan HY, Yip TF, Tsoi KF, Wong VS (2016) Oral nucleos (t) ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Therap 43(7):802–813
Article
CAS
Google Scholar
Yuan J, Peng Y, Hao F-B, Wang Y-Q, Wang C-R, Zhong G-C (2021) No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging 13(5):7147
Article
PubMed
PubMed Central
Google Scholar
Tseng C-H, Hsu Y-C, Chen T-H, Ji F, Chen I-S, Tsai Y-N et al (2020) Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 5(12):1039–1052
Article
PubMed
Google Scholar
Con D, Goodwin T, Majeed A, Roberts S, Kemp W (2021) Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: a network meta-analysis. J Viral Hepat 28(1):40–50
Article
CAS
PubMed
Google Scholar
Geng J, Bao H, Chen Y, Shi L, Geng J, Wang Q et al (2020) Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti-infect Ther 18(8):823–834
Article
CAS
PubMed
Google Scholar
Liu H, Shi Y, Hayden JC, Ryan PM, Rahmani J, Yu G (2020) Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis. Liver Cancer 9(4):468–476
Article
CAS
PubMed
PubMed Central
Google Scholar
Gu L, Yao Q, Shen Z, He Y, Ng DM, Yang T et al (2020) Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. J Gastroenterol Hepatol 35(9):1467–1476
Article
CAS
PubMed
Google Scholar
Choi W-M, Choi J, Lim Y-S (2021) Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 19(2):246–258
Article
CAS
PubMed
Google Scholar
Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X et al (2020) Nucleos (t) ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis. Gut Liver 14(2):232
Article
CAS
PubMed
Google Scholar
Huang Z-H, Lu G-Y, Qiu L-X, Zhong G-H, Huang Y, Yao X-M et al (2022) Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. BMC Cancer 22(1):1–12
Article
CAS
Google Scholar